INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Feb 24, 2020 |
Director, President and Chief Scientific
Trans History: 628
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 118,123 | $420.17 | 517,799 |
| Mar 10, 2020 |
Director, President and Chief Scientific
Trans History: 628
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 1,693 | $485.63 | 517,806 |
| Mar 10, 2020 |
Director, President and Chief Scientific
Trans History: 628
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 345 | $484.72 | 519,499 |
| Dec 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 4,407 | $549.57 | 519,608 |
| Mar 10, 2020 |
Director, President and Chief Scientific
Trans History: 628
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 355 | $483.80 | 519,844 |
| Mar 10, 2020 |
Director, President and Chief Scientific
Trans History: 628
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 100 | $481.68 | 520,199 |
| Mar 10, 2020 |
Director, President and Chief Scientific
Trans History: 628
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 60 | $480.34 | 520,299 |
| Mar 10, 2020 |
Director, President and Chief Scientific
Trans History: 628
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 1,651 | $479.60 | 520,359 |
| Dec 12, 2019 |
Director, President and CSO
Trans History: 628
|
Director, President and CSO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 150,000 | $21.25 | 521,876 |
| Mar 10, 2020 |
Director, President and Chief Scientific
Trans History: 628
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 1,469 | $478.43 | 522,010 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.